文献速递消化系统肿瘤

纳武利尤单抗联合伊匹木单抗在dMMR/MSI-H转移性结直肠癌中持久的临床获益

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-20

CheckMate-142研究报告纳武利尤单抗联合伊匹木单抗治疗既往经治的dMMR/MSI-H转移性结直肠癌:119例患者中研究者评估的客观缓解率(ORR)为55%(95%CI 45.2–63.8),≥12周疾病控制率为80%;中位随访13.4个月,多数缓解持续,12个月无进展生存率和总生存率分别为71%和85%,3–4级治疗相关不良事件发生率为32%。

要点

  • 联合方案在dMMR/MSI-H转移性结直肠癌中ORR达55%,≥12周疾病控制率80%
  • 12个月PFS率71%、OS率85%,多数缓解在数据截止时仍持续
  • 3–4级治疗相关不良事件发生率32%,总体可管理

核心结论

  • 纳武利尤单抗联合伊匹木单抗在dMMR/MSI-H转移性结直肠癌中显示高缓解率、12个月PFS和OS令人鼓舞、安全性可管理,并改善患者报告结局。

研究设计与样本

  • CheckMate-142中纳武利尤单抗联合伊匹木单抗队列,为该人群中免疫联合治疗的最大单研究报道。
  • 给药方案为纳武利尤单抗3 mg/kg联合伊匹木单抗1 mg/kg每3周一次(共4次),随后纳武利尤单抗3 mg/kg每2周一次。
  • 共纳入119例患者,76%既往接受≥两种全身治疗;主要终点为研究者评估的ORR。

主要发现

  • 中位随访13.4个月时,研究者评估的ORR为55%(95%CI 45.2–63.8),≥12周疾病控制率为80%。
  • 中位缓解持续时间未达到,94%的缓解在数据截止时仍在持续。
  • 9个月和12个月PFS率分别为76%和71%,相应OS率分别为87%和85%。
  • 患者报告结局(功能、症状、生活质量)出现统计学显著且有临床意义的改善。
  • 3–4级治疗相关不良事件发生率为32%;13%因研究药物相关不良事件停药,其ORR为63%。

关键数值与推荐

  • ORR 55%(95%CI 45.2–63.8),≥12周疾病控制率80%,中位缓解持续时间未达到。
  • 9个月PFS率76%、12个月PFS率71%;9个月OS率87%、12个月OS率85%。
  • 3–4级治疗相关不良事件32%;因研究药物相关不良事件停药者13%,其ORR 63%。

临床怎么用

  • 对于既往经治的dMMR/MSI-H转移性结直肠癌患者,可考虑纳武利尤单抗联合伊匹木单抗作为治疗选择。
  • 间接比较提示联合方案疗效优于抗PD-1单药,且获益-风险特征有利。

局限性

  • 原文未报告随机对照比较,联合方案与抗PD-1单药的比较为间接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Nivolumab provides clinical benefit (objective response rate [ORR], 31%; 95% CI, 20.8 to 42.9; disease control rate, 69%; 12-month overall survival [OS], 73%) in previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC); nivolumab plus ipilimumab may improve these outcomes. Efficacy and safety results for the nivolumab plus ipilimumab cohort of CheckMate-142, the largest single-study report of an immunotherapy combination in dMMR/MSI-H mCRC, are reported. Patients and Methods Patients received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks. Primary end point was investigator-assessed ORR. Results Of 119 patients, 76% had received ≥ two prior systemic therapies. At median follow-up of 13.4 months, investigator-assessed ORR was 55% (95% CI, 45.2 to 63.8), and disease control rate for ≥ 12 weeks was 80%. Median duration of response was not reached; most responses (94%) were ongoing at data cutoff. Progression-free survival rates were 76% (9 months) and 71% (12 months); respective OS rates were 87% and 85%. Statistically significant and clinically meaningful improvements were observed in patient-reported outcomes, including functioning, symptoms, and quality of life. Grade 3 to 4 treatment-related adverse events (AEs) occurred in 32% of patients and were manageable. Patients (13%) who discontinued treatment because of study drug-related AEs had an ORR (63%) consistent with that of the overall population. Conclusion Nivolumab plus ipilimumab demonstrated high response rates, encouraging progression-free survival and OS at 12 months, manageable safety, and meaningful improvements in key patient-reported outcomes. Indirect comparisons suggest combination therapy provides improved efficacy relative to anti-programmed death-1 monotherapy and has a favorable benefit-risk profile. Nivolumab plus ipilimumab provides a promising new treatment option for patients with dMMR/MSI-H mCRC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018. PMID: 29355075. doi:10.1200/JCO.2017.76.9901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。